Tradelearner2022

$IBRX- Congrats @DrPatrick .. One more amazing milestone. $IBRX Intelligence – Breaking Down the Dr. PSS "Night Shift" Post Dr. Patrick Soon-Shiong was working the night shift for a reason. His 1:00 AM update isn’t just medical jargon. it’s the official signal that $IBRX is moving from a "Bladder Cancer" company to a "Global Cancer Prevention" platform. Here it is in layman's terms. $IBRX 1/ What is Lynch Syndrome? Think of Lynch Syndrome as a genetic "glitch" that gives people an 80% lifetime risk of colon and other cancers. Currently, there is no way to stop it you just wait and hope. • The News: PSS confirmed that the National Cancer Institute (NCI) trial is showing that our combination (ANKTIVA + Vaccine) is working in people before they have cancer. 2/ "Prevention" is the Holy Grail Most drugs try to put out the fire (treat cancer). PSS is showing data that his "Cancer Vaccine" can stop the fire from ever starting. • ANKTIVA acts like a "Most Wanted" poster for your immune system, teaching it to find and kill "pre-cancer" cells before they become a problem. 3/ The "Army" (ALC) is Growing He mentioned ALC (Absolute Lymphocyte Count). • The Simple Version: Your lymphocytes are your body’s internal army. Most cancer treatments (chemo) kill this army. • The Discovery: Independent NCI data confirmed that ANKTIVA actually grows and restores this army. This makes ANKTIVA a "must-have" support tool for almost every other cancer treatment on the market. 4/ Why does this matter for the stock? The market currently values $IBRX based on one drug for one type of cancer. • PSS is signaling that the NCI (The Government) has validated that ANKTIVA is a Platform. * When a platform is proven to prevent cancer and restore the immune system, the company’s "Fair Value" moves from billions to tens of billions. 5/ The Strategy ♟️ Why post this at 1:00 AM before a massive Friday options expiration? • He is providing the "Fundamental Air Cover" to show that while shorts are playing with "ghost shares" to pin the price at $8.99, the real value of this company is in a different stratosphere. Summary: We aren't just looking at a "squeeze." We are looking at the birth of a New Standard of Care in medicine. The science is now independent and validated by the NCI. #IBRX #ANKTIVA #CancerVaccine

$PL- Today was a good day for PL with top notch earnings. It was good to share this analysis earlier in the month even though we did not think at that point that the earrings will be this strong. Congrats to everyone who held.

Great question. It feels like a paradox, but there is a structural reason why shorting continues even when the "borrow" is zero. It’s not necessarily 'Naked Shorting' in the criminal sense, but rather 'Operational Shorting' through legal exemptions. $IBRX. Hopefully this explains. 1/ The Market Maker Exemption (Reg SHO Rule 203b) Under Regulation SHO, "Bona Fide" Market Makers (MMs) are exempt from the Locate Requirement. Their job is to provide liquidity. If you want to buy 10,000 shares and no one is selling, the MM is obligated to sell them to you even if they don't have them. They effectively "short" the stock to fill your buy order, creating a Fail to Deliver (FTD) that they have T+4 to T+6 days to close out. 2/ Operational Shorting (The ETF Loophole) If $IBRX is in an ETF (like XBI), MMs can short the ETF, buy the other stocks in the basket, and leave the $IBRX portion "open." This allows them to create downward pressure on the individual ticker by using the liquidity of the entire fund. This is known as Operational Shorting. 3/ The "Recycling" of Shares. When a retail trader "covers" a short position, those shares immediately go back into the lending pool. In a high-volume battle, the same 1 million shares can be borrowed, sold, covered, and re-borrowed multiple times in a single session. It’s not "new" fuel; it’s the same fuel being siphoned and re-used. 4/ Is it Naked Shorting? Technically, when an MM sells without a locate to "maintain a fair and orderly market," it is a legal form of naked shorting. It only becomes "abusive" if they fail to close out those positions (FTDs) within the legal timeframe. This is why we track the SEC Fails-to-Deliver data it’s the only place where the "ghost shares" eventually show up. The Bottom Line: The shorting feels endless because the "Liquidity Providers" have a legal license to create shares out of thin air to satisfy "demand." The trap snaps shut when a catalyst (like the Saudi 8-K) creates more demand than their exemptions can legally cover.

@Tradelearner022 I am curious if you are able to elaborate how the shorts are generating new shorts daily despite the online claims that the short fuel is "running out". The shorting is seemingly endless. Are we in major naked short territory?

$IBRX- $IBRX Intelligence Report – A Transparent Audit of the March 4th Roadmap Humility in this market is mandatory. On March 4th, we shared a roadmap for $IBRX based on the data we had. Today, March 19th, we are taking a step back to look at what we got right, what we didn’t, and why the price hasn't hit our targets. This is a forensic audit. $IBRX 1/ WHAT WAS ACCOMPLISHED (The Fundamental "Why") ✅ The company’s execution on the science and regulatory front has actually exceeded our original timeline: -FDA sBLA Acceptance: Projected mid-March ➔ Fact: Accepted March 9th. * NCCN Guidelines: Projected end of March ➔ Fact: Hit early on March 17th. -NK Cell Breakthrough: Projected mid-March ➔ Fact: 5B cell manufacturing milestone hit March 13th. The Science is hitting every green light we predicted. 2/ WHAT WAS MISSED (The "Effect" & The "Gap") ❌ - While the science hit, the price action did not follow the projected trajectory. We projected $14.00+ by this week; we are currently at $8.82. -The Miscalculation: Predicting that the market would react logically/immediately to the NCCN win. -The Reality: Underestimating the structural power of the $9.00 Gamma Wall and the 132M share short interest. Even with zero borrow availability, the "house" has successfully pinned the price to protect millions in expiring options. 3/ THE GEOPOLITICAL "X-FACTOR" 🌍 No one could have perfectly timed the macro shift that hit us in the last 3 weeks -The Oil Shock: Crude oil surging past $113 (Middle East tensions) has triggered a "Risk-Off" sentiment across the Nasdaq. -The Weight: When the world is unstable, capital flows out of "High-Growth Biotech" and into "Safety." $IBRX is currently fighting a war on two fronts: the internal short-side mechanics and the external macro pressure. 4/ THE "PENDING" PIECE: Saudi Arabia 🇸🇦 -We projected the Saudi commercial launch for mid-March. -Current Status: The CEO confirmed "Airspace Clearance" and regulatory readiness this week. We are firmly in the window, but we are still waiting on the official 8-K Shipment Confirmation. This is the final piece of the March 4th puzzle that hasn't landed yet. 5/ FINAL REFLECTION Predicting the market is a fool's errand, but tracking the data is a necessity. The Value Gap: The "Cause" (Science/NCCN/FDA) is stronger than ever. The "Effect" (Price) is lagging due to macro noise and structural suppression. Expectation:Higher target remains the fundamental destination, but we are acknowledging that the timeline has been extended by forces beyond our control.

@ZBiddle11 Thank you. We publish these reports based on data.

@Tech_Stamurai @Tradelearner022 This is all accurate information

$IBRX- IBRX Shorts Intelligence Report – March 18, 2026 The shorts are officially out of oxygen. The data from today's session reveals a complete exhaustion of available liquidity. $IBRX. Screenshots attached. 1/ Zero Share Availability. As of 3:13 PM EST, IBKR availability hit N/A (Zero). We watched the borrowable pool dwindle from thousands to just 4 shares before it vanished entirely. The Fact: Shorts no longer have the "firepower" to suppress the bid. They are now playing pure defense. 2/ The Utilization Ceiling Live Ortex data confirms Utilization is at 91% - 100%. Nearly every single share that can be loaned out is already being used to short this stock. There is no "secondary reserve." If a large institution recalls their shares tonight, the shorts are forced into an immediate, non-negotiable buy-back. 3/ Cost to Borrow (CTB) .Heat The average CTB is sitting at 11.77%, with a Max spike of 23.38%. Shorts are paying double-digit interest rates to hold a losing position against a tide of NCCN and Saudi news. This "bleed" accelerates the timeline for Margin Calls. 4/ The Liquidity Trap (Days to Cover). With 132.34 Million shares short (34.90% of the float), the Days to Cover is 3.86. Translation: If an 8-K drops, it would take nearly four full trading days of average volume for every short to exit. They are trapped in a revolving door, and the door is jamming. 5/ Today’s Defensive Stunt. Despite the news, shorts added 2.07 million shares to their net position today. They spent their final "ammo" trying to defend the $9.00 Gamma Wall. The Result: They failed to crush the price, we held the $8.50 floor, and now they have Zero shares left to borrow for tomorrow’s open. The Verdict: The "Spring" is fully coiled. The shorts are all-in, out of ammo, and facing a 4-day exit queue. Any gap-up tomorrow becomes a vertical flight.

$IBRX- IBRX Dark Pool Intelligence Report – March 18, 2026 ( This is a tough one to write as all the data is not readily available.. So there may be errors here.. But here is our best shot. If someone has better data please share and we can analyze) This is our 5th and final report for the night. If you missed our earlier deep-dives on Science, Options, Shorts, or Technicals, check the feed. Now, let’s look at the "Hidden" institutional tape. $IBRX 1/ Off-Exchange Volume Spike. Today, 54.2% of total volume was executed off-exchange (Dark Pools). The Forensic Read: This confirms that more than half of the day's activity was institutional "Whales" filling large blocks away from the public eye. They are positioning heavily ahead of the next catalyst wave. 2/ Dark Pool Net Position (DPNP) -The DPNP for today finished at +$12.4M (Bullish). Translation: Despite the midday price chop, there was a net "Buy" imbalance in the shadows. Institutions are absorbing the shares that shorts are "naked selling" to defend the $9.00 wall. 3/ Verify the Data (For the Skeptics) -we track the tape in real-time so you don’t have to, but we always encourage independent verification. You can check the aggregate off-exchange volume yourself. Review the weekly/daily aggregates. (Note: Official FINRA public data has a reporting delay; our real-time reports utilize professional TRF feeds to catch these prints the second they hit.) The Verdict: The whales are positioned. The science is validated. The shorts are out of ammo. The technicals are coiled. The dark pools are net-long. The data across all 5 reports has converged. See you at the opening bell.

$IBRX- $IBRX Technical Intelligence Report – March 18, 2026 Price action doesn't lie. The $IBRX chart is screaming "Accumulation" as we head into the most critical 48 hours of the year. Here is the technical breakdown. $IBRX. Charts included. 1/ The Daily Setup (Coiling for Breakout)- The Daily chart shows a textbook "Higher Low" formation at $7.81. We are currently trading above the 20-day and 50-day EMA, which have now curved upward to provide a "Launchpad" support zone. The price is being compressed between the $8.40 support and the $9.00 resistance. 2/ Volume Analysis. Notice the "Bullish Divergence" in volume. Sell volume is drying up on red days, while green candles are seeing aggressive "Buying Spikes." This confirms that institutions are absorbing every share the shorts are throwing at the bid. (Accumulation) is in full effect. 3/ ADX & Directional Movement (+DI/-DI) .The ADX is beginning to trend upward from the 20 level, signaling that a new, powerful trend is being born. The +DI (Green) is firmly above the -DI (Red), meaning the bulls have officially seized control of the primary trend direction. 4/ Bollinger Band Compression .On the 1-hour chart (right), the Bollinger Bands are "Squeezing" tighter than they have in weeks. In technical analysis, extreme compression always leads to extreme expansion. With the $9.00 Gamma Walllooming, the path of least resistance is up. 5/ Key Levels to Watch Immediate Support: $8.40 (The line in the sand). Pivot Resistance: $8.92 - $9.00 (The "Squeeze Trigger"). Target 1: $12.43 (Previous High). The Verdict: We are in the "Quiet Before the Storm." The chart is a coiled spring, the indicators are bullish, and the shorts are trapped against a wall of technical support. The technicals have officially converged with the science.

$IBRX- IBRX Options Intelligence Report – March 18, 2026- March 18th 2026. Data included below. The fuse is lit. The options market is currently pricing in a massive "Gamma Event" for the Friday expiration. $IBRX 1/ The $9.00 Gamma Wall -Today’s data confirms the largest concentration of Open Interest is sitting at the $9.00 Strike for this Friday (Mar 20). Current OI: 27,670 Call contracts. The Mechanics: If we cross $9.00, Market Makers must "delta-hedge" by buying millions of shares, creating a feedback loop of vertical price action. 2/ Unusual Institutional Flow.We tracked two "Smart Money" alerts today that indicate this isn't just a retail trade: 8:40 AM: A massive 2,029 Call Block was bought for the April 16th $10 Strike. 9:29 AM: Multiple Bullish Sweeps hit the tape, signaling institutions are bypassing limit orders to get long immediately. They aren't waiting for the 8-K; they are front-running it. 3/ The Put/Call Extremity The Volume Put/Call Ratio (PCR) finished today at an astonishing 0.09. Interpretation: For every 1 Put traded, there were over 11 Calls bought. Bearish protection has completely evaporated. The market is positioned 100% for a "Binary Breakout." 4/ Expected Move & Max Pain Max Pain: Currently sitting at $9.00. Expected Move: The options market is pricing in a ±12% swing ($1.00+) by Friday's close. The Divergence: While Max Pain is $9.00, the "Institutional Sweeps" are targeting $10.00+, suggesting the "Pain" will be felt entirely by the shorts. The floor is set. The ceiling is thinning.

$IBRX- Congrats Dr PSS. @DrPatrick The Scientific Convergence is Here. -$IBRX 1/ The Breakthrough Rockefeller University just published a landmark study (Mar 16, 2026) showing that a single tumor injection can trigger a "Vaccine Factory" that kills metastatic cancer body-wide. The research confirms that activating the IL-15 pathway is the key to unlocking this systemic response. [Link: sciencedaily.com/releases/2026/…] 2/ The Clinical Reality .This isn't just a lab theory. We've seen the brain scans on NewsNation. We’ve seen the QUILT-3.078 data: 19/23 Glioblastoma patients still alive as of Jan 2026. ANKTIVA is the first FDA-approved IL-15 agonist the exact "fuel" the Rockefeller scientists are calling for. 3/ Data Point: The "IL-15 Synergy" The Rockefeller study (antibody 2141-V11) confirms that CD40 therapy is most effective when paired with exogenous IL-15. Why? CD40 "activates" the immune cells, but IL-15 (ANKTIVA) "multiplies" them. It’s the difference between a single soldier and an entire army. 4/ Data Point: The "TLS" Command Center The research proved that this treatment creates Tertiary Lymphoid Structures (TLS) internal "immune command centers" inside the tumor. This explains the long-term durable responses seen in $IBRX trials. We aren't just killing cells; we are re-training the body to hunt cancer forever. 5/ The 1-2-3 Punch Yesterday: $IBRX secured NCCN 2026 Guideline status (Commercial Floor). Today: Global research validates the platform (Scientific Ceiling). Imminent: The Saudi shipment lands (Operational Execution).

$IBRX- Under the Hood of the $IBRX "Shakeout" Yesterday was a hard day. We saw a massive gap to $9.30 on confirmed NCCN news, only to see the "Algos" and shorts slam it back to red by the close. If you only look at the price, you're missing the war. Let’s look under the hood. 1. The "Naked" Short Attack Yesterday, $IBRX traded 28.6M shares. Forensic scan shows that shorts didn't exit they doubled down at the $9.30 peak to prevent a $10 Gamma Squeeze. Current Short Interest: ~132M shares. The Trap: They "spent" their ammunition to turn the screen red, but they couldn't break the $7.81 floor. They are now more over-leveraged than they were on Monday. 2. Liquidity is GONE Look at the latest IBKR data: 4 shares available to borrow. Not 4,000. Four. Utilization is pegged at the ceiling. There is no more "ammo" to suppress the next leg up. When the Saudi 8-K drops, there is no one left to sell only millions of shorts forced to buy. 3. The Saudi "Delay" is a Logistical Fact CEO Richard Adcock just confirmed at the Citizens Conference: Shipments were delayed by regional conflict/airspace closures. CRITICAL: Product is READY and they have now received AIRSPACE CLEARANCE. The "60-day" window wasn't a failure of execution; it was a physical flight delay that is now RESOLVED. 4. The Bottom Line The NCCN update (Step 1) is a permanent fundamental win for insurance revenue. The Saudi Shipment (Step 2) is now cleared for takeoff. $IBRX #IBRX #ImmunityBio #ShortSqueeze

$IBRX- The update: Adcock confirmed product is READY and crucially they have now received AIRSPACE CLEARANCE. The planes are moving. The 60-day window was 'missed' by 72 hours because of a war, not a lack of execution. The 'Second Shoe' is in the air. marketbeat.com/instant-alerts…

@BillMur81205942 Thanks for the update.

@Tradelearner022 Product was flown in last week. Patients were ready

$IBRX- Fact-Checking the Saudi Launch $IBRX Saudi Launch & The 60-Day Clock There is confusion about the "March 15 deadline." Let’s look at the verified SEC data and SFDA regulatory mandates that anchor this timeline. 1- The Regulatory Anchor (Jan 14, 2026) The Saudi Food and Drug Authority (SFDA) granted Accelerated Approval for ANKTIVA + Checkpoint Inhibitors in metastatic NSCLC (Lung Cancer). Fact: This is a global first. KSA is currently the only jurisdiction on Earth authorized for this life-saving indication.+ SEC Verification: In the Feb 23, 2026, Form 8-K (Exhibit 99.1), ImmunityBio explicitly stated: "Commercial launch in Saudi Arabia is planned within 60 days of approval." The Math: 60 days from Jan 14 = March 15, 2026. 2- The Pricing Certificate (Feb 20, 2026) Commercialization cannot happen without a price. Fact: On Feb 20, IBRX confirmed: "The Registration Certificate of Pharmaceutical Product with pricing has been issued to ImmunityBio from the Saudi FDA." Impact: This certificate is the legal "Green Light" for the first commercial sale and distribution. 3- Industrial Infrastructure: Cigalah & BioPharma This is a "State-Level" launch. IBRX established a wholly-owned Saudi subsidiary and partnered with Cigalah Healthcare (Naghi & Sons Group). Reliability: Cigalah is a $2B+ distribution giant. CEO Rich Adcock confirmed on March 3: "Product shipments were ready to commence." Strategy: Working directly with the Ministry of Investment (MISA) to bypass standard global supply bottlenecks. 4- The "Material Event" Filing (The 8-K): Under SEC rules, a "First International Commercial Sale" is a material event. The Squeeze: 132M shares are short with 100% utilization. A Form 8-K dropping Sunday/Monday confirming the shipment turns "hope" into "verified revenue." Bottom Line: The March 15 date isn't a guess it’s the regulatory deadline cited in sworn financial documents. The transition from R&D to Global Powerhouse is happening now. #IBRX #ANKTIVA #SaudiVision2030 #Biotech #ShortSqueeze Links for Reference Feb 23 SEC 8-K: 700% Revenue Growth & Saudi Launch Timeline ir.immunitybio.com/news-releases/… Feb 20 Press Release: SFDA Pricing Certificate & Cigalah Partnership ir.immunitybio.com/news-releases/… Jan 14 Press Release: World-First Lung Cancer Approval ir.immunitybio.com/news-releases/…

@DrPatrick - Thanks Dr PSS for reposting. What a honor to be following your company. We all are rooting for the amazing work you are doing for humanity.

$IBRX-Here is the breakdown of the PSS post and the best way to understand it. 1. The "Special Forces" Analogy (The Clinical Edge) The Message: Most cancer treatments (like chemo) are "carpet bombs" that damage everything. ANKTIVA is "Special Forces" it specifically recruits and arms NK Cells and Killer T-Cells. Key Stat: Highlight the Hazard Ratio (HR) of 0.4 for duration of response. This means ANKTIVA-treated patients have a 60% lower risk of cancer returning compared to the standard of care. 2. The "Leonardo" Connection (The Industrial Edge) The Message: PSS is "connecting the dots" between the science and the machine. The NANT Leonardo AI-robotic platform is the factory that makes the "Special Forces." The 1:10 Shift: This is your strongest data point. 1:10 donor-to-dose ratio is no longer a theory it’s a robotic reality that scales globally. 3. Global Geopolitical Signaling The Message: PSS is signaling that while the US regulatory path is a "fight," the rest of the world (starting with the March 15 Saudi Launch) is already embracing the future. The "Enlightenment": He is essentially saying the "BioShield" isn't just a drug; it’s a global infrastructure for cancer care. 4. European Validation (EAU26) The timing of this post, coinciding with the EAU26 (European Association of Urology) congress in London, is a signal of geographical expansion. Global Standard: He is signaling that European clinicians now "understand" that ANKTIVA is not just a secondary treatment but a foundational "Special Forces" unit that can cure cancer by activating the innate and adaptive immune systems simultaneously. 5. Slide in the background The slide in the background of his post emphasizes Key Mechanisms: Long-term Memory: One of the most important signals here is "Promotes durable immune memory without exhaustion." The Message to Shorts: This is a direct counter-narrative to those betting on short-term results. PSS is signaling that ANKTIVA creates a permanent internal defense system (Memory T cells), which is the key to the "curative" potential he mentions. THE ENLIGHTENMENT HAS BEGUN. Dr. Patrick Soon-Shiong (@DrPatSoonShiong) just validated the "Leonardo" robotic thesis. This isn't just a biotech story; it's an industrial revolution. Special Forces: ANKTIVA recruits the elite killers (NK & T-cells) to seek and destroy, while ignoring "Tregs" (the tumor’s shield). Leonardo Robotics: The AI-driven backbone enabling the 1:10 dose yieldand 90% COGS reduction. Global Access: "Certain countries" are already moving. The Saudi launch on March 15 is just the start.Standard of Care is being disrupted in real-time. #IBRX #ANKTIVA #Immunotherapy #ShortSqueeze

$KINS- The Forensic Case for $KINS: Fundamentals vs. Activism Headline: A data-driven breakdown of the $KINS "Value Gap." Why record earnings and a 13D filing are creating a unique liquidity event. 1/ The Earnings Baseline ($2.88 EPS) -Kingstone ($KINS) isn't just "improving"; it’s hitting historical peaks. FY 2025 EPS: $2.88 (Diluted) Net Income: $40.8M Combined Ratio: 64.2% (Q4) P/E Ratio: 5.3x (vs. industry avg 12x-15x). The company is trading at a significant discount to its peer group despite a 43% ROE. 2/ The Activist Catalyst (March 12) -The Fortunoff Group flipped from a passive 13G to an Active 13D filing. Stake: 7.6% (1.1M shares). Demand: A formal "Strategic Sale" process. Support: Fortunoff holds 90,400 call options at the $15 strike. This creates a mechanical "floor" as market makers must hedge these ITM calls, absorbing sell-side liquidity. 3/ Management’s Defensive Signaling Within 24 hours of the activist filing, @KingstoneKINS began a proactive social media campaign: Message: Signaling a path to $500M in direct premiums by 2029. Focus: Entry into the California market in Q2 2026. The Read: This is classic "X Diplomacy." Management is anchoring the valuation high to force any potential bidder to pay a massive premium for future growth rather than current price. 4/ The Convergence Timeline Feb 2026: Record FY results prove structural profitability. Mar 12: Activist 13D demands a sale. Mar 13: Management counters with long-term "Independence" goals. Next 72 Hours: The Board's formal response is the key catalyst. Historically, these acknowledgments trigger "Wolf Pack" institutional buying. 5/ The Outlook (Next 2–3 Weeks)- The "Technical V-Shape" is in motion. Immediate Resistance: $16.17 (50-Day EMA). Gap Fill Target: $16.80 – $17.14. With high insider ownership and a rare NY license, any buyout rumor could accelerate the stock toward its $21.50 analyst consensus. Conclusion: We are seeing a clash between "Growth at any price" (Management) and "Exit now for value" (Activist). In either scenario, the current 5.3x P/E looks structurally unsustainable. Watching the tape for institutional block trades. #ValueInvesting #KINS #Insurance #Activism

$IBRX- Today, Friday, March 13, 2026, was indeed a pivotal day for ImmunityBio (IBRX). The stock surged over 10% to close near $8.91 at one point during the day and settled down around $8.40, effectively breaking a "7 out 8 day red streak" and reversing a sharp technical decline. The excitement stems from a "perfect storm" of three massive catalysts that hit the wire simultaneously, directly addressing the biggest fears investors had about the company's future. 1. The "World Bank of NK Cells" (Manufacturing Milestone) The primary driver for today's move was the announcement that ImmunityBio has successfully industrialized its cell therapy production. The Scale: A single donor collection can now yield 5 billion highly pure NK cells. The "1:10 Math": This provides 8 to 10 therapeutic doses per patient with a 12-day turnaround. This effectively "fixes" the business model by drastically lowering the cost of production and proving the company can scale globally. The Goal: Dr. Patrick Soon-Shiong described this as the foundation for a "World Bank of Natural Killer Cells,"where treatments can be universally donated without the need for complex HLA matching. 2. The Saudi Arabia "Fuse" (March 15 Deadline) The market is currently pricing in the March 15th Saudi Launch deadline (this Sunday). Launch Confirmation: Today's manufacturing news serves as the "logistical proof" that ImmunityBio can actually supply the Middle East. Lung Cancer Edge: Saudi Arabia is the first country in the world to approve ANKTIVA for Lung Cancer (NSCLC). The partnership with Cigalah Healthcare is expected to trigger revenue-generating shipments starting this weekend. 3-Outpatient Safety = Massive TAM Expansion This is the single biggest "hidden" catalyst for the Saudi Arabia launch. The Data: QUILT-3.076 Phase 1 results: 0% Grade 4/5 Adverse Events and 0% Cytokine Storm. The Impact: Traditional CAR-T often requires 7–14 days of inpatient hospitalization due to toxicity risk. ImmunityBio’s 100% outpatient safety profile allows the drug to be administered in local clinics, expanding the Total Addressable Market (TAM) to the 80% of patients who don't live near specialized "certified" hospitals. 4-Cracking the "Checkpoint Resistance" Code This addresses why they are a "Universal Backbone." The Data: NCI-led preclinical data (March 2026) showed a p<0.0001 increase in MHC-Class I expression. The Impact: 62% of neuroendocrine tumors (like SCLC) are "invisible" to current drugs because they lack MHC-I. By "turning the lights on," ImmunityBio isn't just treating cancer; it is sensitizing tumors so that every other immunotherapy (like Keytruda or Opdivo) can finally work. Lets see what next week brings.. But closing green was a good sign. But as always no-one what happens next only Market knows.. So we continue to speculate and use the data publicly available to analyze .#ImmunityBio #ANKTIVA #Biotech